MedPath

Advance Biofactures Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)

Phase 1
Completed
Conditions
Fibroids, Uterine
Leiomyoma
Interventions
Other: Saline
First Posted Date
2016-09-07
Last Posted Date
2019-07-10
Lead Sponsor
Advance Biofactures Corporation
Target Recruit Count
15
Registration Number
NCT02889848
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath